[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364024-105":59,"doc-detail-364024-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","timing-and-patterns-of-relapse-related-events-following-adjuvant-cdk46-inhibitors-combined-with-endocrine-therapy-in-patients-with-hr-positive-her2-negative-early-breast-cancer","Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer","","Adjuvant CDK4/6 inhibitors improve outcomes in HR+/HER2− early breast cancer, but recurrence still occurs. Early relapse is linked to poor prognosis, yet relapse timing and recurrence patterns after this therapy were unclear. Analyzing pivotal adjuvant trials, iDFS and OS were extracted from Kaplan–Meier curves up to 60 months using PlotDigitizer. The study compared early versus total iDFS events, first iDFS-event types and patterns, and adverse events.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/timing-and-patterns-of-relapse-related-events-following-adjuvant-cdk46-inhibitors-combined-with-endocrine-therapy-in-patients-with-hr-positive-her2-negative-early-breast-cancer/364024/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/timing-and-patterns-of-relapse-related-events-following-adjuvant-cdk46-inhibitors-combined-with-endocrine-therapy-in-patients-with-hr-positive-her2-negative-early-breast-cancer/364024.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question does the study address?","Question",{"text":112,"@type":113},"The study investigates when relapse-related iDFS events occur and what recurrence patterns emerge after adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− early breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were iDFS and OS data obtained?",{"text":117,"@type":113},"iDFS and OS were extracted from Kaplan–Meier curves using PlotDigitizer, evaluated over a consistent follow-up window up to 60 months.",{"name":119,"@type":110,"acceptedAnswer":120},"What proportion of iDFS events were early relapse-related?",{"text":121,"@type":113},"Early relapse-related events (≤36 months) accounted for 63.5%, 63.9%, 62.7%, and 60.8% of total iDFS events across the reported inhibitor-containing arms, broadly similar to control arms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364024,1790472845,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Cancer Medicine  \n|  RESEARCH ARTICLE  OPEN ACCESS \u003Cbr>Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer\u003Cbr>Huihui Chen1,2  | Shijie Wu1,2  | Yangyang Shan3 | Xianan Guo1,2 | Wei Lu2,4  | Yiding Chen1,2  | Yunxiang Zhou1,2 \u003Cbr>1Department of Breast Surgery and Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China | 2Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China | 3Department of Breast Surgery, The People's Hospital of Suichang County, Lishui, China | 4Zhejiang Provincial Clinical Research Center for Cancer, Hangzhou, China\u003Cbr>Correspondence: Yunxiang Zhou ([yxzhou@zju.edu.cn](yxzhou@zju.edu.cn)) | Yiding Chen ([ydchen@zju.edu.cn](ydchen@zju.edu.cn))\u003Cbr>Received: 27 February 2026 | Revised: 18 July 2026 | Accepted: 19 August 2026\u003Cbr>Keywords: adjuvant therapy | CDK4/6 inhibitors | endocrine therapy | HR+/HER2− early breast cancer | invasive disease-free survival |\n| --- |\n| ABSTRACT\u003Cbr>Background: Adjuvant CDK4/6 inhibitors improve outcomes in hormone receptor-positive, HER2-negative (HR+/HER2−) early breast cancer, yet some patients still experience recurrence. Early relapse in particular is associated with poor prognosis, but the timing and patterns of recurrence following this treatment remain undefined, limiting further therapeutic strategy development.\u003Cbr>Materials and Methods: We analyzed pivotal trials of adjuvant CDK4/6 inhibitors in early-stage HR+/HER2 − breast cancer to assess the temporal distribution of iDFS events. Invasive disease-free survival (iDFS) and overall survival (OS) data were extracted from Kaplan–Meier curves using PlotDigitizer. Events were evaluated up to 60 months, a time frame with consistent follow-up across trials. The primary endpoint was the proportion of early versus total iDFS events and deaths by 60 months. The types and patterns of first iDFS event, as well as adverse events, were also discussed.\u003Cbr>Results: The 5-year iDFS in CDK4/6 inhibitor-containing arms were as follows: 85.5%(NATALEE), 83.1%(monarchE), 84.2%(PALLAS), 67.9%(PENELOPE-B) . Early relapse-related events (≤36months) accounted for 63.5%, 63.9%, 62.7%, and 60.8% of total iDFS events, respectively, all proportions broadly similar to those observed in the control arms. The temporal distribution of iDFS event rates within consecutive 6-month intervals appeared generally consistent. Distant metastasis constituted the predominant form of the first iDFS event, with bone as the most common metastatic site. The most frequently reported adverse events included neutropenia and diarrhea. Diarrhea was more prevalent with abemaciclib, whereas neutropenia occurred more frequently with palbociclib.\u003Cbr>Conclusion: Adjuvant CDK4/6 inhibitors (ribociclib and abemaciclib) demonstrated iDFS benefits in monarchE and NATALEE. In our exploratory analysis, the temporal distribution of iDFS events appeared broadly consistent across trials, with no obvious |\n|  |\n| Abbreviations: AIs, aromatase inhibitors; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCNE1, cyclin E1; CDK4/6, cyclin-dependent kinase 4 and 6; CNS, central nervous system; CPS-EG, clinical pathological staging-estrogen receptor grading; ctDNA, circulating tumor DNA; EBC, early breast cancer; ER, estrogen receptor; ET, endocrine therapy; FGFR, fibroblast growth factor receptor; HR+/HER2−, hormone receptor-positive, human epidermal growth factor receptor 2-negative; iDFS, invasive disease-free survival; OS, overall survival; PFS, progression-free survival; RB, retinoblastoma; SERMs, selective estrogen receptor modulators. |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, d","cbCaiqYkz5elnqbV","https://ap.wps.com/l/cbCaiqYkz5elnqbV","pdf",709731,12,"English","# Abstract\n# Introduction\n## Background and rationale\n## CDK4/6 inhibitors in HR+/HER2− breast cancer\n# Materials and Methods\n## Study design and endpoints\n## Time window and event extraction\n# Results\n## 5-year iDFS outcomes by trial\n## Early relapse-related event proportion\n## First iDFS event patterns\n## Adverse events","[{\"question\":\"What clinical question does the study address?\",\"answer\":\"The study investigates when relapse-related iDFS events occur and what recurrence patterns emerge after adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− early breast cancer.\"},{\"question\":\"How were iDFS and OS data obtained?\",\"answer\":\"iDFS and OS were extracted from Kaplan–Meier curves using PlotDigitizer, evaluated over a consistent follow-up window up to 60 months.\"},{\"question\":\"What proportion of iDFS events were early relapse-related?\",\"answer\":\"Early relapse-related events (≤36 months) accounted for 63.5%, 63.9%, 62.7%, and 60.8% of total iDFS events across the reported inhibitor-containing arms, broadly similar to control arms.\"}]","Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer | PDF",1790155185,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc8d51556bcc820d1283bd6f996e07a7.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bf0a268101aa334057492bd90bb6db1.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f3f6f1fed77772a81b80e45a45b8748.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38a732230ec6f7e846598fa06b3db718.webp",980,1287]